Recent evidence suggests that inhibiting MNP-induced ferroptosis, particularly by targeting the NFE2L2 (encoding Nrf2) gene, holds promise as an anti-AD therapeutic strategy [177,178]. This evidence concerns the gene NFE2L2 and Alzheimer disease.